The chemokine coreceptor 5 (CCR5) antagonists are antiretroviral agents with an
extracellular, host-targeted mechanism of action against HIV. Maraviroc, the first-in-class …

The advent of next-generation sequencing technologies has greatly impacted genomic
research by providing a means for increasing the amount of sequence information in a cost …

BACKGROUND: Clinical trials of CCR5 antagonists have relied on the phenotypic
determination of HIV-1 coreceptor usage. Few phenotypic assays are available, with few …

Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity
version of Trofile as reference ass Page 1 NEW MICROBIOLOGICA, 33, 195-206, 2010 …

Objectives Maraviroc is the first licensed chemokine co-receptor 5 (CCR5) co-receptor
antagonist in clinical practice. It is currently being used in patients harbouring exclusively …

CCR5 antagonists have recently entered the HIV armamentarium. This novel class of drugs
inhibit viral entry blocking host cellular receptors, and therefore display unique mechanisms …

Introduction: Maraviroc is the only C-chemokine receptor 5 (CCR5) antagonist approved for
the treatment of infection with HIV. This article reviews the safety and efficacy of maraviroc in …

The use of resistance testing in the management of HIV-1-inf... : Current Opinion in HIV and
AIDS The use of resistance testing in the management of HIV-1-infected patients : Current …

Dual/mixed-tropic HIV-1 strains are predominant in a significative proportion of patients,
though few information is available regarding the genetic characteristics, quasispecies …

Deep sequencing is able to generate a complete picture of the retroviral quasi-species in a
patient. We demonstrate that the unprecedented power of deep sequencing in conjunction …